Phathom Pharmaceuticals (PHAT) Q3 2024 earnings summary

Executive summary

• Achieved significant milestones in Q3 2024, including FDA approval for Voquezna in non-erosive GERD and expanded commercial access surpassing 80% of U.S. commercial lives, with over 143,000 prescriptions filled since launch.

• Raised $130 million in equity financing, strengthening the balance sheet to $335 million in cash and supporting continued investment and growth.

• Continued focus on commercial execution, brand awareness, and expanding prescriber base, especially among primary care physicians.

• VOQUEZNA recognized with industry awards and positive media coverage for innovation in GERD treatment.

• The company is evaluating further development and partnerships in Europe and Canada.

Financial highlights

• Q3 2024 net revenues were $16.4 million, up over 120% sequentially, with gross profit of $14 million and gross margin of 86%.

• Non-GAAP SG&A expenses were $71.8 million, up $53.1 million year-over-year, mainly due to commercial infrastructure and DTC campaign investments.

• Non-GAAP R&D spend was $7.4 million, down 32% year-over-year but up 22% sequentially.

• Non-GAAP adjusted net loss was $67.9 million, or $1.05 per share, improved from $73.3 million, or $1.25 per share, in Q2.

• Cash and cash equivalents stood at $334.7 million as of September 30, 2024.

Outlook and guidance

• Confident in achieving full-year 2024 consensus; will provide formal guidance when trends are more established.

• Management expects current cash, projected revenues, and available term loan funds to be sufficient to achieve cash flow positivity.

• Expect continued investment in commercial and DTC activities into 2025, with anticipated volatility in Q1 due to typical industry seasonality.

• Plans to initiate a Phase 2 program for Eosinophilic Esophagitis in H1 2025, pending FDA feedback.

• Real-world data from VOQUEZNA's Non-Erosive GERD launch will inform potential Phase 3 As Needed dosing program.